Branded Legacy Inc (BLEG) Fair Value & Analysis
Healthcare · US · Market cap $55.0K
Branded Legacy Inc
BLEG · US
Fair value as of: Jul 29, 2026
From 6 valuation models · updated 12 days ago
Share price +50.5% over the past month.
Below-average quality, and screening another 44% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0128). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- The models converge in a tight band ($0.0119 to $0.0128), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0005 – $35,040 · fair‑value band $0.0119 – $0.0128 · the $0.0152 price screens above the $0.0085 fair value. Dashed = 300-day average. As of Jul 29, 2026.
Analysis
Branded Legacy Inc (BLEG) currently trades at $0.0152, while our model-based Fair Value estimate is $0.0085, implying the stock looks roughly 44.1% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $87.6K. Revenue declined 46.9% year over year. Net debt stands at $1.7M. Fundamentals as of Jul 29, 2026
Our scenario range runs from $0.0119 (bear case) to $0.0128 (bull case); at $0.0152, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -44%, BLEG screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Growth DCF ($0.3200) versus Multiples ($0.1900). Highest evidence: Growth DCF (80).
Notify me when BLEG reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 14
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Branded Legacy Inc engages in the commercial development of hemp and cannabinoid-infused beverages in Central Florida. It provides CBD topicals and tinctures, and hemp coffees and teas. The company was formerly known as Elev8 Brands, Inc. and changed its name to Branded Legacy Inc in May 2020. Branded Legacy Inc.
Full company description
Branded Legacy Inc engages in the commercial development of hemp and cannabinoid-infused beverages in Central Florida. It provides CBD topicals and tinctures, and hemp coffees and teas. The company was formerly known as Elev8 Brands, Inc. and changed its name to Branded Legacy Inc in May 2020. Branded Legacy Inc. was incorporated in 1981 and is headquartered in Melbourne, Florida.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Branded Legacy Inc reported revenue of $492K in FY2025 versus $64.3K in FY2021, a compound +66.3%/yr. Reported net income was −$382K in FY2025.
BLEG screens 44% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Branded Legacy Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Branded Legacy Inc (BLEG) overvalued or undervalued?
What is the fair value of BLEG?
What is the quality score of BLEG?
What is the revenue of Branded Legacy Inc (BLEG)?
What is the net profit margin of BLEG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Branded Legacy Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.